Atomic resolution crystal structures of HIV-1 protease and mutants V82A and I84V with saquinavir

Proteins: Structure, Function and Genetics

Volumn 67, Issue 1, 2007, Pages 232-242

  Tie, Yunfeng ^a   Kovalevsky, Andrey Y ^a   Boross, Peter ^b   Wang, Yuan Fang ^a   Ghosh, Arun K ^c,d   Tozser, Jozsef ^b   Harrison, Robert W ^a   Weber, Irene T ^a,e  

^a GEORGIA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c PURDUE UNIVERSITY   (United States)

^d PURDUE UNIVERSITY   (United States)

^e NONE   (United States)

Author keywords

AIDS; Darunavir; Drug resistance; Protease inhibitor

Indexed keywords

ANTIRETROVIRUS AGENT; DARUNAVIR; PROTEINASE INHIBITOR; SAQUINAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CRYSTAL STRUCTURE; ENZYME STRUCTURE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROGEN BOND; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEINASE INHIBITION; VIRUS RESISTANCE; X RAY DIFFRACTION;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; CRYSTALLIZATION; CRYSTALLOGRAPHY, X-RAY; DRUG RESISTANCE; HIV PROTEASE; HIV PROTEASE INHIBITORS; SAQUINAVIR;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33847361008     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.21304     Document Type: Article

References (44)

1. Palella FJ, Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med 1998;338:853-860.
2. Tozser J, Oroszlan S. Proteolytic events of HIV-1 replication as targets for therapeutic intervention. Curr Pharm Des 2003;9:1803-1815.
3. Prejdova J, Soucek M, Konvalinka J. Determining and overcoming resistance to HIV protease inhibitors. Curr Drug Targets Infect Disord 2004;4:137-152.
4. Koh Y, Nakata H, Maeda K, Ogata H, Bilcer G, Devasamudram T, Kincaid JF, Boross P, Wang YF, Tie Y, Volarath P, Gaddis L, Harrison RW, Weber IT, Ghosh AK, Mitsuya H. A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitors (PI) UIC-94017 (TMC114) potent against multi-PI-resistant HIV in vitro. Antimicrob Agents Chemother 2003;47:3123-3129.
5. Craig JC, Duncan IB, Hockley D, Grief C, Roberts NA, Mills JS. Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. Antiviral Res 1991;16:295-305.
6. Deminie CA, Bechtold CM, Stock D, Alam M, Djang F, Balch AH, Chou TC, Prichard M, Colonno RJ, Lin PF. Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication. Antimicrob Agents Chemother 1996;40:1346-1351.
7. Tamalet C, Pasquier C, Yahi N, Colson P, Poizot-Martin I, Lepeu G, Gallais H, Massip P, Puel J, Izopet J. Prevalence of drug resistant mutants and virological response to combination therapy in patients with primary HIV-1 infection. J Med Virol 2000;61:181-186.
8. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quintero JC, Rhodes A, Robbins HL, Roth E, Shivaprakash M, Titus D, Yang T, Teppler H, Squires KE, Deutsch PJ, Emini EA. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995;374:569-571.
9. Jacobsen H, Hanggi M, Ott M, Duncan IB, Owen S, Andreoni M, Vella S, Mous J. In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies. J Infect Dis 1996;173:1379-1387.
10. Jacobsen H, Yasargil K, Winslow DL, Craig JC, Krohn A, Duncan IB, Mous J. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology 1995;206:527-534.
11. Boucher C. Rational approaches to resistance: using saquinavir. AIDS 1996;10 (Suppl 1):S15-S19.
12. Wlodawer A, Erickson JW. Structure-based inhibitors of HIV-1 protease. Annu Rev Biochem 1993;62:543-585.
13. Wlodawer A, Vondrasek J. Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. Annu Rev Biophys Biomol Struct 1998;27:249-284.
14. Kovalevsky AY, Liu F, Leshchenko S, Ghosh AK, Louis JM, Harrison RW, Weber IT. Ultra-high resolution crystal structure of HIV-1 protease mutant reveals two binding sites for clinical inhibitor TMC114. J Mol Biol 2006;363:161-173.
15. Kovalevsky AY, Tie Y, Liu F, Boross PI, Wang YF, Leshchenko S, Ghosh AK, Harrison RW, Weber IT. Effectiveness of nonpeptide clinical inhibitor TMC-114 on HFV-1 protease with highly drug resistant mutations D30N, I50V, and L90M. J Med Chem 2006;49:1379-1387.
16. Liu F, Boross PI, Wang YF, Tozser J, Louis JM, Harrison RW, Weber IT. Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S. J Mol Biol 2005;354:789-800.
17. Liu F, Kovalevsky AY, Louis JM, Boross PI, Wang YF, Harrison RW, Weber IT. Mechanism of drug resistance revealed by the crystal structure of the unliganded HFV-1 protease with F53L mutation. J Mol Biol 2006;358:1191-1199.
18. Mahalingam B, Wang YF, Boross PI, Tozser J, Louis JM, Harrison RW, Weber IT. Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site. Eur J Biochem 2004;271:1516-1524.
19. Tie Y, Boross PI, Wang YF, Gaddis L, Hussain AK, Leshchenko S, Ghosh AK, Louis JM, Harrison RW, Weber IT. High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains. J Mol Biol 2004;338:341-352.
20. Tie Y, Boross PI, Wang YF, Gaddis L, Liu F, Chen X, Tozser J, Harrison RW, Weber IT. Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs. FEBS J 2005;272:5265-5277.
21. Krohn A, Redshaw S, Ritchie JC, Graves BJ, Hatada MH. Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere. J Med Chem 1991;34:3340-3342.
22. Prabu-Jeyabalan M, Nalivaika EA, King NM, Schiffer CA. Viability of a drug-resistant human immunodeficiency virus type 1 protease variant: structural insights for better antiviral therapy. J Virol 2003;77:1306-1315.
23. Hong L, Zhang XC, Hartsuck JA, Tang J. Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: insights into the mechanisms of drug resistance. Protein Sci 2000;9:1898-1904.
24. Munshi S, Chen Z, Yan Y, Li Y, Olsen DB, Schock HB, Galvin BB, Dorsey B, Kuo LC. An alternate binding site for the P1-P3 group of a class of potent HIV-1 protease inhibitors as a result of concerted structural change in the 80s loop of the protease. Acta Crystallogr 2000;56 (Part 4):381-388.
25. FDA approves new HIV treatment for patients who do not respond to existing drugs. US Food and Drug Administration (FDA), 2006.
26. Louis JM, Wondrak EM, Copeland TD, Smith CA, Mora PT, Oroszlan S. Chemical synthesis and expression of the HIV-1 protease gene in E. coli. Biochem Biophys Res Commun 1989;159:87-94.
27. Wondrak EM, Louis JM. Influence of flanking sequences on the dimer stability of human immunodeficiency virus type 1 protease. Biochemistry 1996;35:12957-12962.
28. Bagossi P, Kadas J, Miklossy G, Boross P, Weber IT, Tozser J. Development of a microtiter plate fluorescent assay for inhibition studies on the HTLV-1 and HIV-1 proteinases. J Virol Methods 2004;119:87-93.
29. Otwinowski Z, Minor W. Processing of X-ray diffraction data in oscillation mode. Methods Enzymol 1997;276:307-326.
30. Navaza J. AMoRe: An automated package for molecular replacement. Acta Crystallogr A 1994;50:157-163.
31. Sheldrick GM, Schneider TR. SHELXL: High resolution refinement. Methods Enzymol 1997;277:319-343.
32. Jones TA, Zou JY, Cowan SW, Kjeldgaard M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A 1991;47:110-119.
33. Esnouf RM. Further additions to MolScript version 1.4, including reading and contouring of electron-density maps. Acta Crystallogr D: Biol Crystallogr 1999;55:938-940.
34. Gulnik SV, Suvorov LI, Liu B, Yu B, Anderson B, Mitsuya H, Erickson JW. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 1995;34:9282-9287.
35. Klabe RM, Bacheler LT, Ala PJ, Erickson-Viitanen S, Meek JL. Resistance to HIV protease inhibitors: a comparison of enzyme inhibition and antiviral potency. Biochemistry 1998;37:8735-8742.
36. Velazquez-Campoy A, Todd MJ, Freire E. HIV-1 protease inhibitors: enthalpic versus entropic optimization of the binding affinity. Biochemistry 2000;39:2201-2207.
37. King NM, Prabu-Jeyabalan M, Nalivaika EA, Wigerinck P, de Bethune MP, Schiffer CA. Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J Virol 2004;78:12012-12021.
38. Ishima R, Freedberg DI, Wang YX, Louis JM, Torchia DA. Flap opening and dimer-interface flexibility in the free and inhibitor-bound HIV protease, and their implications for function. Struct Fold Des 1999;7:1047-1055.
39. Rose RB, Craik CS, Stroud RM. Domain flexibility in retroviral proteases: structural implications for drug resistant mutations. Biochemistry 1998;37:2607-2621.
40. Swairjo MA, Towler EM, Debouck C, Abdel-Meguid SS. Structural role of the 30's loop in determining the ligand specificity of the human immunodeficiency virus protease. Biochemistry 1998;37:10928-10936.
41. Zoete V, Michielin O, Karplus M. Relation between sequence and structure of HIV-1 protease inhibitor complexes: a model system for the analysis of protein flexibility. J Mol Biol 2002;315:21-52.
42. Piana S, Carloni P, Parrinello M. Role of conformational fluctuations in the enzymatic reaction of HIV-1 protease. J Mol Biol 2002;319:567-583.
43. Piana S, Carloni P, Rothlisberger U. Drug resistance in HIV-1 protease: flexibility-assisted mechanism of compensatory mutations. Protein Sci 2002;11:2393-2402.
44. Olsen DB, Stahlhut MW, Rutkowski CA, Schock HB, vanOlden AL, Kuo LC. Non-active site changes elicit broad-based cross-resistance of the HIV-1 protease to inhibitors. J Biol Chem 1999;274:23699-23701.